BR9712424A - Composição farmacêutica antagonista deneurotrofina - Google Patents
Composição farmacêutica antagonista deneurotrofinaInfo
- Publication number
- BR9712424A BR9712424A BR9712424-9A BR9712424A BR9712424A BR 9712424 A BR9712424 A BR 9712424A BR 9712424 A BR9712424 A BR 9712424A BR 9712424 A BR9712424 A BR 9712424A
- Authority
- BR
- Brazil
- Prior art keywords
- lower alkyl
- pharmaceutical composition
- alkyl
- optionally substituted
- neurotrophin
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 239000005557 antagonist Substances 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 9
- 108010025020 Nerve Growth Factor Proteins 0.000 abstract 2
- 102000007072 Nerve Growth Factors Human genes 0.000 abstract 2
- 150000002148 esters Chemical class 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 229920002472 Starch Polymers 0.000 abstract 1
- 125000001769 aryl amino group Chemical group 0.000 abstract 1
- 125000005102 carbonylalkoxy group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000014511 neuron projection development Effects 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 235000019698 starch Nutrition 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/14—Aza-phenalenes, e.g. 1,8-naphthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
"COMPOSIçãO FARMACêUTICA ANTAGONISTA DENEUROTROFINA". Uma composição farmacêuticacompreendendo um composto de formula (I) onde R1 éselecionado dentre , inter alia, alquila, aril-alquila inferior, alquilainferior-heterocíclico, carbonato-alquila inferior; aminoopcionalmente substituído; benzidimaz 2-il; fenila opcionalmentesubstituído; alquila inferior (R5), (R6) onde um de R5 ou R6 éselecionado dentre H e alquila inferior e o outro é selecionadodentre carboxila, carboxi-alquila inferior e alcóxi carbonila inferior;NHCH2CH20X onde X representa um éster hidrolizável in vivo; eR2 e R3 são independentemente selecionados dentre H, NO2,Halo, di(alquila inferior)amino, ciano, C(O)OH, fenil-S-, alquilainferior, e Z(O)OR7 onde Z é selecionado dentre C e S e R7 éselecionado dentre H, alquila amino inferior e arilamino; ou saisfarmaceuticamente aceitáveis ou certos ésteres hidrolizáveis invivo ou amidos do mesmo, em uma quantidade efetiva para inibiratividade mediada por neurotrofina e um portador apropriado, édescrita. As composições são úteis para inibir atividade mediadapor neurotrofina tal como o crescimento de neurito que ocorre emalguns estados de doenças neurodegenarativas.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9621902.7A GB9621902D0 (en) | 1996-10-21 | 1996-10-21 | Neurotrophin antagonist compositions |
GBGB9710904.5A GB9710904D0 (en) | 1997-05-27 | 1997-05-27 | Neurotropin antagonist compositions |
PCT/CA1997/000779 WO1998017278A1 (en) | 1996-10-21 | 1997-10-20 | Neurotrophin antagonist compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9712424A true BR9712424A (pt) | 2001-11-20 |
Family
ID=26310264
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9712424-9A BR9712424A (pt) | 1996-10-21 | 1997-10-20 | Composição farmacêutica antagonista deneurotrofina |
Country Status (14)
Country | Link |
---|---|
US (4) | US20020169182A1 (pt) |
EP (1) | EP0930883B1 (pt) |
JP (1) | JP2001503397A (pt) |
KR (1) | KR20000052691A (pt) |
AT (1) | ATE315397T1 (pt) |
AU (1) | AU728523C (pt) |
BR (1) | BR9712424A (pt) |
CA (1) | CA2268450C (pt) |
DE (1) | DE69735090T2 (pt) |
DK (1) | DK0930883T3 (pt) |
ES (1) | ES2257768T3 (pt) |
IL (1) | IL129475A0 (pt) |
NZ (1) | NZ335291A (pt) |
WO (1) | WO1998017278A1 (pt) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20000052691A (ko) | 1996-10-21 | 2000-08-25 | 스트라칸 그라함 | 뉴로트로핀 길항제 조성물 |
CZ20011792A3 (cs) * | 1998-11-25 | 2001-09-12 | Merck Patent Gmbh | Derivát benzo[de]isochinolin-1,3-dionu, způsob jeho přípravy, jeho použití a farmaceutický prostředek, který ho obsahuje |
AU760136B2 (en) * | 1998-11-25 | 2003-05-08 | Merck Patent Gmbh | Substituted benzo(DE)isoquinoline-1,3-diones |
US6468990B1 (en) * | 1999-05-17 | 2002-10-22 | Queen's University At Kingston | Method of inhibiting binding of nerve growth factor to p75 NTR receptor |
US6492380B1 (en) * | 1999-05-17 | 2002-12-10 | Queen's University At Kingston | Method of inhibiting neurotrophin-receptor binding |
FR2807660A1 (fr) * | 2000-04-13 | 2001-10-19 | Warner Lambert Co | Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques |
WO2004032870A2 (en) | 2002-10-08 | 2004-04-22 | Rinat Neuroscience Corp. | Methods for treating post-surgical pain by admisnistering a nerve growth factor antagonist and compositions containing the same |
UA80447C2 (en) | 2002-10-08 | 2007-09-25 | Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic | |
US9498530B2 (en) | 2002-12-24 | 2016-11-22 | Rinat Neuroscience Corp. | Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same |
PT2270048E (pt) | 2002-12-24 | 2016-02-10 | Rinat Neuroscience Corp | Anticorpos anti-ngf e métodos de utilização dos mesmos |
US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
US7655231B2 (en) | 2003-02-19 | 2010-02-02 | Pfizer Inc. | Methods for treating pain by administering a nerve growth factor antagonist and an NSAID |
FR2862967B1 (fr) * | 2003-12-01 | 2006-08-04 | Sanofi Synthelabo | Derives de (4-phenylpiperazin-1-yl)acylpiperidine, leur preparation et leur application en therapeutique |
FR2862968B1 (fr) * | 2003-12-01 | 2006-08-04 | Sanofi Synthelabo | Derives de 4-[(arylmethyl)aminomethyl]piperidine, leur preparation et leur application en therapeutique |
HUE037549T2 (hu) | 2004-04-07 | 2018-09-28 | Rinat Neuroscience Corp | Eljárások csontrákfájdalom kezelésére idegi növekedési faktor antagonista antitest beadásával |
GB0419850D0 (en) * | 2004-09-07 | 2004-10-13 | Angeletti P Ist Richerche Bio | Therapeutic agents |
US20070099900A1 (en) * | 2005-09-15 | 2007-05-03 | Painceptor Pharma Corporation | Methods of modulating neurotrophin-mediated activity |
WO2009039635A1 (en) * | 2007-09-24 | 2009-04-02 | Painceptor Pharma Corporation | Methods of modulating neurotrophin-mediated activity |
FR2953839A1 (fr) * | 2009-12-14 | 2011-06-17 | Sanofi Aventis | Nouveaux derives d'(heterocycle-piperidine condensee)-(piperazinyl)-1alcanone ou d'(heterocycle-pyrrolidine condensee)-(piperazinyl)-1alcanone et leur utilisation comme inhibiteurs de p75 |
LT3333188T (lt) | 2010-08-19 | 2022-06-10 | Zoetis Belgium S.A. | Anti-ngf antikūnai ir jų panaudojimas |
EP2606894A1 (en) | 2011-12-20 | 2013-06-26 | Sanofi | Novel therapeutic use of p75 receptor antagonists |
CN104364264B (zh) | 2012-06-06 | 2018-07-24 | 硕腾服务有限责任公司 | 犬源化抗ngf抗体和其方法 |
WO2019177690A1 (en) | 2018-03-12 | 2019-09-19 | Zoetis Services Llc | Anti-ngf antibodies and methods thereof |
US20230348608A1 (en) | 2022-04-27 | 2023-11-02 | Regeneron Pharmaceuticals, Inc. | Treatment Of Arthropathy Based Upon Stratification Of Osteoarthritis Polygenic Risk Score |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US525841A (en) * | 1894-09-11 | Baling-press | ||
US627129A (en) * | 1899-06-20 | Collar-edge-ironing machine | ||
US3821383A (en) * | 1972-07-10 | 1974-06-28 | Ayerst Mckenna & Harrison | Compositions for and a method of treating diabetic complications |
US4006238A (en) | 1975-08-28 | 1977-02-01 | E. R. Squibb & Sons, Inc. | Use of 2-(hydroxyalkyl)-1H-benz[de]isoquinoline-1,3(2H)-diones as anti-allergy agents |
ES459497A1 (es) | 1977-06-04 | 1978-04-16 | Made Labor Sa | Un metodo para la preparacion industrial de naftalimidas y sus derivados. |
US4254109A (en) * | 1979-11-08 | 1981-03-03 | Ayerst, Mckenna & Harrison Inc. | 1H-Benz[de]isoquinoline-2(3H)-acetic acid derivatives |
RU2051677C1 (ru) * | 1982-02-10 | 1996-01-10 | Украинский научно-исследовательский институт эндокринологии и обмена веществ | Средство для профилактики и лечения диабетических осложнений, ангиопатий, нейропатий, катаракты |
US5183821A (en) | 1983-09-19 | 1993-02-02 | Laboratories Knoll, S.A. | Method for treating leukemias using N-(2-dimethylaminoethyl)-3-amino-1,8-naphthalimide for treating leukemias and solid tumors |
IT1214618B (it) * | 1985-06-27 | 1990-01-18 | I P A International Pharmaceut | Composti e composizioni farmaceutiche per la terapia di retinopatie e neuropatie diabetiche. |
DE3635711A1 (de) | 1986-10-21 | 1988-04-28 | Knoll Ag | 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung |
DE3707652A1 (de) * | 1987-03-10 | 1988-09-22 | Knoll Ag | Verwendung von benzo(de)isochinolin-1,3-dionen zur herstellung von arzneimitteln |
DE3707651A1 (de) | 1987-03-10 | 1988-09-22 | Knoll Ag | Bis-naphthalimide, ihre herstellung und verwendung |
US5420137A (en) | 1989-07-11 | 1995-05-30 | Knoll Ag | Amonafide salts |
US5356906A (en) * | 1989-10-27 | 1994-10-18 | The Du Pont Merck Pharmaceutical Company | (N-phthalimidoalkyl) piperidines useful as treatments for psychosis |
CA2030129A1 (en) | 1989-11-29 | 1991-05-30 | Thomas Saupe | 1,8-napthalenedicarboximides as antidotes |
US5342942A (en) | 1992-06-09 | 1994-08-30 | Warner-Lambert Company | Pyrazoloquinazolone derivatives as neurotrophic agents |
DE4232739A1 (de) | 1992-09-30 | 1994-03-31 | Knoll Ag | Neue asymmetrisch substituierte bis-Naphthalimide |
IL110460A (en) | 1993-08-18 | 2001-01-11 | Basf Ag | Bite-naphthalimides, their preparation and pharmaceutical preparations containing them |
US6291247B1 (en) | 1994-05-11 | 2001-09-18 | Queen's University At Kingston | Methods of screening for factors that disrupt neurotrophin conformation and reduce neurotrophin biological activity |
GB9616105D0 (en) | 1996-07-31 | 1996-09-11 | Univ Kingston | TrkA binding site of NGF |
KR20000052691A (ko) | 1996-10-21 | 2000-08-25 | 스트라칸 그라함 | 뉴로트로핀 길항제 조성물 |
CA2319672C (en) | 1997-02-07 | 2011-01-04 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
WO1998052919A1 (fr) | 1997-05-21 | 1998-11-26 | Japan Tobacco Inc. | Derives de phtalimide et produit pharmaceutique contenant ces derives |
WO2000000472A1 (en) | 1998-06-30 | 2000-01-06 | Du Pont Pharmaceuticals Company | 5-ht7 receptor antagonists |
JP3357662B2 (ja) | 1998-07-03 | 2002-12-16 | 大鵬薬品工業株式会社 | ナフタルイミドベンズアミド誘導体 |
US6492380B1 (en) | 1999-05-17 | 2002-12-10 | Queen's University At Kingston | Method of inhibiting neurotrophin-receptor binding |
US6468990B1 (en) | 1999-05-17 | 2002-10-22 | Queen's University At Kingston | Method of inhibiting binding of nerve growth factor to p75 NTR receptor |
-
1997
- 1997-10-20 KR KR1019990703479A patent/KR20000052691A/ko not_active Application Discontinuation
- 1997-10-20 DK DK97909098T patent/DK0930883T3/da active
- 1997-10-20 JP JP51875698A patent/JP2001503397A/ja not_active Ceased
- 1997-10-20 BR BR9712424-9A patent/BR9712424A/pt not_active Application Discontinuation
- 1997-10-20 IL IL12947597A patent/IL129475A0/xx not_active IP Right Cessation
- 1997-10-20 AT AT97909098T patent/ATE315397T1/de not_active IP Right Cessation
- 1997-10-20 NZ NZ335291A patent/NZ335291A/en unknown
- 1997-10-20 DE DE69735090T patent/DE69735090T2/de not_active Expired - Fee Related
- 1997-10-20 WO PCT/CA1997/000779 patent/WO1998017278A1/en active IP Right Grant
- 1997-10-20 ES ES97909098T patent/ES2257768T3/es not_active Expired - Lifetime
- 1997-10-20 CA CA002268450A patent/CA2268450C/en not_active Expired - Fee Related
- 1997-10-20 EP EP97909098A patent/EP0930883B1/en not_active Expired - Lifetime
- 1997-10-20 AU AU46968/97A patent/AU728523C/en not_active Ceased
-
2001
- 2001-01-11 US US09/758,917 patent/US20020169182A1/en not_active Abandoned
-
2005
- 2005-07-13 US US11/179,610 patent/US7291629B2/en not_active Expired - Fee Related
-
2007
- 2007-09-28 US US11/905,406 patent/US20080287484A1/en not_active Abandoned
-
2009
- 2009-04-28 US US12/453,032 patent/US20090215815A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
DE69735090D1 (de) | 2006-04-06 |
EP0930883A1 (en) | 1999-07-28 |
AU728523B2 (en) | 2001-01-11 |
WO1998017278A1 (en) | 1998-04-30 |
CA2268450A1 (en) | 1998-04-30 |
JP2001503397A (ja) | 2001-03-13 |
AU728523C (en) | 2001-08-09 |
US20090215815A1 (en) | 2009-08-27 |
US7291629B2 (en) | 2007-11-06 |
DE69735090T2 (de) | 2006-09-14 |
KR20000052691A (ko) | 2000-08-25 |
US20080287484A1 (en) | 2008-11-20 |
IL129475A0 (en) | 2000-02-29 |
CA2268450C (en) | 2008-08-05 |
AU4696897A (en) | 1998-05-15 |
DK0930883T3 (da) | 2006-05-22 |
NZ335291A (en) | 2001-02-23 |
ATE315397T1 (de) | 2006-02-15 |
US20020169182A1 (en) | 2002-11-14 |
US20050250807A1 (en) | 2005-11-10 |
EP0930883B1 (en) | 2006-01-11 |
ES2257768T3 (es) | 2006-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9712424A (pt) | Composição farmacêutica antagonista deneurotrofina | |
IT1314184B1 (it) | Composizioni farmaceutiche per la terapia di condizioni di stressossidativo | |
NZ501346A (en) | Valinyl aromatic beta amino acid dipeptide compounds having fungicidal activity and their agronomic use | |
ATE277066T1 (de) | Bicyclonucleosid-analoga | |
ID29452A (id) | 4-okso-1,4-dihidro-3-quinolinkarboksamida sebagai agen-agen antivirus | |
IL144826A0 (en) | Amide compounds and pharmaceutical compositions containing the same | |
NO20003018D0 (no) | Triazinangiogenese-inhibitorer | |
FI954609A (fi) | 1-amidinofenyyli-pyrrolidoneja, -piperidinoneja ja -atsetinoneja verihiutaleiden kasaantumisen inhibiittoreina | |
MY109846A (en) | Dual inhibitors of no synthase and cyclooxygenase, process for their preparation and therapeutical compositions containing them | |
BG106020A (en) | Inhibitors of impdh enzyme | |
ATE287715T1 (de) | Verwendung von oxidosqualencyclasehemmer zur senkung des cholesterinblutspiegels | |
DE60019317D1 (de) | Chinazolinderivate | |
CA2280850A1 (en) | Quinazolinone-containing pharmaceutical compositions for prevention of neovascularization and for treating malignancies | |
NO991494D0 (no) | <beta>-sulfonylhydroksaminsyrer som matriksmetalloproteinaseinhibitorer | |
HUP0100732A2 (hu) | Amidvegyületet és azolszármazékot tartalmazó szinergetikus hatású fungicid kompozíció és alkalmazása | |
CA2250861A1 (en) | Cyclic adhesion inhibitors | |
PL341050A1 (en) | Heterocyclic cytoxic agents | |
ES2093091T3 (es) | Derivado de glutation. | |
TNSN97092A1 (ar) | مثبطات انزيم بروتيني فلزي وتركيبات صيدلانية تحتوي على تلك المثبتطات واستخدامها الصيدلاني وطرق ومركبات وسيطة مفيدة لتحضير التركيبات المذكورة. | |
KR950002753A (ko) | 연골 보호제 | |
BR0315400A (pt) | Composto, composição farmacêutica, e, métodos para tratar ou prevenir câncer em um paciente e para inibir o crescimento de uma célula de câncer ou célula neoplástica | |
HUP0101996A2 (hu) | Szinergetikus fungicid hatóanyag keverék és alkalmazása | |
BR0307266A (pt) | Compostos que inibem a atividade do fator xa | |
BR0209776A (pt) | Composições de inibidores seletivos de ciclo oxigenase-2 e radiação para inibição ou prevenção de doença cardiovascular | |
HUP0202340A2 (hu) | Hatóanyagként kondenzált heterociklusos vegyületeket tartalmazó gyógyszerkészítmények és alkalmazásuk |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |